Typhoid conjugate vaccine (TCV) is likely to be cost-effective in countries with high typhoid incidence, high cost of typhoid treatment, and/or high death rates from typhoid. Below, explore the predicted vaccine impact and cost-effectiveness for 54 Gavi-eligible countries.
Key Results Accross Countries
Predicted TCV Impact
Typhoid conjugate vaccines (TCVs) have the potential to significantly reduce the burden of disease due to typhoid.
Toggle between the maps to see the predicted percent reduction in typhoid cases in all 54 Gavi-eligible countries in the 10 years after introducing routine TCV immunization at 9 months of age as part of various introduction strategies.*
Move with your cursor to a country to see the percentage value of reduction for that country.
Predicted impact 10 years after introducing TCV
* Vaccine coverage in each country is based on the 2018 Gavi demand forecast.
Minimum price a decision-maker needs to be willing-to-pay for a unit health gain for vaccination to become preferred over no vaccination in terms of cost-effectiveness.
For each of the 54 Gavi-eligible countries, this chart shows the lowest price a decision-maker needs to be willing-to-pay for one disability-adjusted life-year (DALY) averted, thanks to vaccination, at which any of the three TCV vaccination strategies becomes preferred compared to no vaccination, in terms of cost-effectiveness.
If the decision-maker’s willingness-to-pay threshold is greater than or equal to this value, then TCV vaccination is considered cost-effective. Each country should establish its own threshold based on local preferences.
Lowest cost per DALY averted at which vaccination is more cost-effective than no vaccination (in USD2016)
Dividing the cost per DALY averted by each country's gross domestic product (GDP) per capita gives a value to determine whether the intervention is cost-effective or not.
* NOTE: For conjecture only; model input adjustments outside of published assumptions are not supported by evidence and any adjusted results- have not been corroborated by the researchers or TyVAC.
NOTE: The background, methods, results and discussion of this analysis are presented in detail in Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study. The content presented here should be considered together with this manuscript. Any changes to inputs away from those considered in the manuscript cannot be cited or referenced as such.
